For personal use only H1 2025 Results Telix Pharmaceuticals ASX: TLX | NASDAQ: TLX 21 August 2025 Disclaimer This presentation should be read together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX) and the U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website. The information contained in this presentation is not intended to be an offer for subscription, invitation or ...

Key Takeaways GEHC posts 7% revenue growth and steady EPS, reaffirming FY25 outlook.GEHC momentum is driven by Imaging demand, diagnostics and AI expansion.GEHC leverages global reach, innovation and efficiency to sustain growth.GE HealthCare Technologies (GEHC) posted a solid second-quarter 2025 earnings report, underscoring its ability to deliver growth amid a challenging macro backdrop. Revenues rose 7% year over year to $5.25 billion, driven by strength in Imaging, Patient Care Solutions and Pharmaceuti ...

Core Insights - Tempus AI, Inc. (TEM) is rapidly expanding its partnerships in oncology and neuroscience, utilizing its AI platforms, Lens and Next, to enhance precision medicine [1] Partnerships and Collaborations - Tempus has initiated a multi-year collaboration with The Abrams Research Center at Northwestern University to utilize its AI-powered Lens platform for genomic data analysis in Alzheimer's research [2] - In February, Tempus partnered with the Institute for Follicular Lymphoma Innovation to create a deidentified data library in Lens, aimed at accelerating treatment development for follicular lymphoma [2] - In May, Tempus formed a strategic collaboration with Boehringer Ingelheim to advance cancer pipeline research, building on previous joint efforts [3] - Earlier this year, Tempus and Stemline Therapeutics announced a collaboration to enhance oncology treatments using the AI-enabled Next platform [3] - In January, Tempus partnered with Genialis to leverage its multimodal dataset for developing new RNA-based algorithms across various cancer types [4] Industry Comparisons - Sophia Genetics expanded its partnership with AstraZeneca to utilize its AI Factories for breast cancer therapy research, while also collaborating with Result Laboratorium for pharmacogenomics insights [5] - AbbVie announced collaborations with ADARx Pharmaceuticals and Gubra A/S to develop therapeutics across multiple disease areas, including oncology [6] Stock Performance - Over the past year, Tempus AI shares have increased by 35.9%, outperforming the industry growth of 21.4% and the S&P 500's 15.9% improvement [7] Valuation Metrics - Tempus currently trades at a forward 12-month Price-to-Sales (P/S) ratio of 9.38, significantly higher than the industry average of 5.87 [10] Earnings Estimates - Recent estimates for Tempus AI's loss per share have shown mixed movements for 2025 and 2026, with current estimates at -0.16 for Q3 2025 and -0.70 for the current year [11][12]

Biodesix recently validated Thermo Fisher’s tissue-based Oncomine Dx Express Test for solid tumors on the Genexus Dx Integrated SequencerLOUISVILLE, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leader in personalized diagnostics, announced that the company is designated as a Thermo Fisher Scientific Center of Excellence (COE) as part of Thermo Fisher’s collaborative initiative to advance NGS-based diagnostics. The services provided to Thermo Fisher are an example of Biodesix Dev ...

SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced it has commenced an underwritten public offering (the “offering”) of (i) pre-funded warrants to purchase shares of iBio’s common stock, and (ii) accompanying Series G warrants each representing the right to purchase (a) a fraction of a share of iBio’s common stock, or a pre-funded warrant in lieu thereof, and (b) Series H warrants each representing the right to purc ...

Core Insights - Aptose Biosciences Inc. reported financial results for Q2 2025, highlighting progress in the TUSCANY triplet trial for treating newly diagnosed acute myeloid leukemia (AML) with tuspetinib-based therapy [1][2] Financial Performance - The net loss for Q2 2025 was $7.0 million, a decrease from $7.3 million in Q2 2024. For the first half of 2025, the net loss was $12.6 million, down from $16.9 million in the same period of 2024 [11][12] - Research and development expenses for Q2 2025 were $3.3 million, down from $4.4 million in Q2 2024. For the first half of 2025, these expenses totaled $5.7 million, compared to $10.9 million in the first half of 2024 [14][17] Clinical Development - The TUSCANY trial is advancing with promising safety and efficacy results for the tuspetinib (TUS) combination therapy, showing complete responses (CRs) across various genetic backgrounds in AML patients [4][5] - The Cohort Safety Review Committee (CSRC) recommended escalating the tuspetinib dose from 120 mg to 160 mg based on positive safety data [4][5] - Data from the TUSCANY trial was presented at the European Hematology Association (EHA) 2025 Congress, indicating that TUS can be safely combined with standard treatments [5][6] Corporate Developments - Aptose entered a loan agreement with Hanmi Pharmaceutical for up to $8.5 million to support the development of tuspetinib [6][9] - The company has been upgraded to trade on the OTCQB Market, enhancing its visibility among investors [9] - Aptose selected Ernst & Young as its new independent auditor and will hold a reconvened shareholder meeting on August 22, 2025 [9][10] Research and Development Focus - The company is focusing on the development of precision oncology therapies, particularly for hematological malignancies, with tuspetinib as a lead candidate [17][19] - Program costs for tuspetinib were $2.2 million for Q2 2025, down from $2.7 million in Q2 2024, attributed to reduced clinical trial activities [18]

Financial Data and Key Metrics Changes - In H1 2025, group revenues reached €371 million, a 5% decrease compared to 2024, primarily due to an 11% decline in DMPD revenues to €269 million, influenced by a temporary decline in BMS revenues [17][18] - Just Evotec Biologics (JEP) achieved €102.2 million in revenue, reflecting a 16% year-over-year growth, driven by strong demand from non-Sandoz and DoD customers [18][19] - Adjusted group EBITDA was negative €1.9 million, with a strong contribution of €7.5 million from JEP, offsetting lower operational leverage from the DMPD segment [19][20] Business Line Data and Key Metrics Changes - DMPD segment saw an 11% revenue decline, attributed to a temporary effect in the BMS collaboration and continued softness in the early drug discovery market [10][17] - JEP segment outperformed with a 16% revenue growth year-over-year, driven by expanding customer base and strong demand [13][19] - R&D spending decreased by 35% year-over-year, from €29.3 million in 2024 to €19 million in 2025, aligning with strategic focus [19] Market Data and Key Metrics Changes - The biotech funding landscape remains complex, with early-stage investments lagging behind later-stage funding, leading to cautious spending behavior in early-stage R&D [14][15] - Signs of a modest recovery in funding are emerging, with expectations for a more normalized distribution of funding and project flow in the coming quarters [15] Company Strategy and Development Direction - The company unveiled a new strategy in April 2025, focusing on pioneering drug discovery and development, operational excellence, and sustainable profitable growth [5][8] - The business model is evolving towards two core segments: discovery and preclinical development (DMPD) and Just Evotec Biologics (JEP), with an emphasis on reducing complexity and enhancing accountability [9][12] - The planned sale of the Toulouse site to Sandoz is part of the strategy to lean into JEP's capabilities as a scalable technology provider, marking a significant milestone in the asset-light model [13][35] Management's Comments on Operating Environment and Future Outlook - Management noted ongoing market challenges but expressed confidence in the progress made and the transformation efforts underway [5][6] - The company anticipates improved visibility towards midterm goals following the Sandoz transaction, with a bold aspiration of 8% to 12% revenue CAGR and greater than 20% EBITDA margin by 2028 [40][41] - Management highlighted the importance of leveraging technology and scientific leadership to create new business opportunities and enhance value creation [27][30] Other Important Information - The company is navigating a cautious funding environment, particularly in early-stage biotech, while maintaining a strong pipeline and operational rigor [14][15][20] - The expansion of the molecular patient database is a key strategic initiative, enhancing capabilities in precision medicine and drug discovery [23][25] Q&A Session Summary Question: Guidance for 2025 and recovery in funding - Management does not expect a significant impact from VC funding recovery in the second half of 2025 [44][45] Question: Breakdown of R&D business revenues - Management indicated that the transactional part of the R&D business is shrinking relative to integrated and large partnerships, which are growing [46][47] Question: Value transfer from the Sandoz deal - Management emphasized the importance of technology capabilities and ongoing revenue streams from milestones and royalties, but did not provide specific numbers [48][49][53] Question: Trends in DMPD segment and customer spending - Management noted cautious spending behavior among biotech customers and mixed dynamics among pharma partners [56][60][62] Question: Pricing environment and competition - Management acknowledged increased price sensitivity in the transactional segment but emphasized the value provided in integrated partnerships [69][71] Question: Geographic market dynamics - Management observed different market behaviors, with stronger traction in East Asia compared to the US and Europe [73][74] Question: Mix of JEP business revenue sources - Management stated that current revenue from JEP is a package of drug production and licensing, with a focus on monetizing assets fully [75][78] Question: Rationale for the sale of the Toulouse site - Management reiterated that the sale aligns with the strategic direction and timing for the company [86] Question: Kidney disease projects and revenue proportion - Management highlighted ongoing investments in kidney disease research and partnerships with major pharma companies [90][91] Question: Customer base for JEP growth - Management confirmed that growth in JEP is derived from a mix of small and large pharma customers, primarily in earlier-stage development [94]

Summary of Oculus Conference Call Company Overview - Oculus is a global biopharma company listed on Nasdaq, focusing on innovative ophthalmology and neuro-ophthalmology candidates targeting significant market opportunities [3][4] Core Assets 1. **OCS-01 (OptiReach)**: A high concentration dexamethasone eye drop for diabetic macular edema (DME), currently in phase three with readout expected in 2026 [3][4] 2. **Privelceptor (OCS-05)**: A first-in-class neuroprotective candidate for acute optic neuritis, currently in development [4][13] 3. **Lickamenimab (OCS-02)**: A novel topical anti-TNF candidate for dry eye disease, starting phase two/three trials in the second half of the year [4][28] Market Insights - **Diabetic Macular Edema (DME)**: - Affects 37 million patients globally, expected to grow to over 50 million by 2045 [6] - Current treatments are invasive, leading to low patient compliance; 56% of diagnosed patients are untreated [6][7] - The U.S. addressable patient population for OCS-01 is estimated at 1.3 million, with a market value of approximately $3 billion [12] - **Acute Optic Neuritis (AON)**: - No approved treatments currently exist; estimated 65,000 patients in the U.S. [15] - High unmet need for neuroprotective therapies [16][24] - **Multiple Sclerosis (MS)**: - Affects approximately 2.8 million worldwide, with a market valued above $20 billion [24] - Oculus aims to address relapses and neuroprotection during acute periods [25] - **Dry Eye Disease**: - A large and unsatisfied market; only 13% of patients experience lasting relief after 12 months [30] - Lickamenimab shows five times better efficacy in signs and seven times better in symptoms for patients with the TNF-R1 genotype [31][32] Clinical Trial Results - **OCS-01**: - Achieved 7.6 letter gains in best corrected visual acuity (BCVA) at week 12 [11] - 27.4% of patients had a 15-letter gain by week 12 [11] - Well tolerated with no unexpected adverse events [11] - **Privelceptor**: - Achieved primary safety endpoint and significant improvements in visual function and neuroprotection in the ACQUITY trial [20][21] - 43% improvement in GCIPL thickness and 30% in RNFL thickness at month six [20][21] - **Lickamenimab**: - Demonstrated rapid treatment effects in both signs and symptoms of dry eye disease [31] - Well tolerated with low incidence of adverse events [34] Future Plans - Anticipate top-line results from OCS-01 phase three program in 2026, with NDA filing in the second half of 2026 [41] - Plans to initiate phase two/three trials for AON and dry eye disease in upcoming quarters [41] - Strong balance sheet to support ongoing development activities [41] Conclusion - Oculus is positioned with a robust portfolio of differentiated products addressing significant unmet needs in ophthalmology and neuro-ophthalmology [40] - Upcoming catalysts across multiple assets and indications are expected to drive growth and shareholder value [40][41]

Financial Data and Key Metrics Changes - Total revenues for Q2 2025 increased by 81% year over year to $181.4 million [8][27] - Molecular profiling services revenues rose to $162.9 million, an increase of 86% year over year [8][27] - Pharma R&D services revenue grew to $18.5 million, reflecting a 49% year over year increase [8][27] - Gross margins improved to 62.7%, up from 37.5% in the same quarter last year [12][29] - Positive adjusted EBITDA of $16.7 million and positive free cash flow of $5.9 million were achieved [13][32] Business Line Data and Key Metrics Changes - Clinical case volumes exceeded 50,000 profiles, representing a 22% year over year growth [10][14] - Average selling price (ASP) for molecular profiling increased to $3,256 per profile, a 52% year over year growth [10][12] - Caris Assure for therapy selection saw a 56% year over year case volume growth [10] Market Data and Key Metrics Changes - The penetration rate for comprehensive genomic profiling (CGP) remains low at around 30%, indicating significant growth opportunities [15][101] - The company has contracted with national commercial payers covering over 170 million lives, enhancing market access [38][55] Company Strategy and Development Direction - The company aims to leverage its technology platform for precision medicine, focusing on whole exome and whole transcriptome assays [7][8] - The long-term strategy includes expanding into MRD monitoring and early detection markets [13][26] - The company emphasizes the importance of partnerships and collaborations, such as the Caris Precision Oncology Alliance, to enhance its market position [17][101] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory, citing strong demand for their services and the potential for further ASP increases [39][90] - The company anticipates continued positive trends in revenue and profitability, with guidance for total revenue in FY 2025 expected to be between $675 million and $685 million [33][34] Other Important Information - The company completed its IPO in June 2025, raising net proceeds of $519 million, significantly strengthening its balance sheet [13][27] - The company has integrated with approximately 2,500 clinical sites, with over 60% of orders transmitted electronically [15] Q&A Session Summary Question: Can you discuss the ASP update in the quarter? - The ASP for tissue was primarily driven by the increase in MyCancerSEQ cases, which represented 78% of tissue cases in Q2 [36][38] Question: What is the guidance for the year and the assumptions behind it? - The guidance assumes mid to high teens growth in clinical volumes for the second half of the year, with a total revenue expectation of $675 million to $685 million [33][34][62] Question: How is the company addressing the competitive environment in tissue profiling? - The company believes it has a differentiated platform and is well-positioned to capture market share as the penetration of CGP remains low [101][102] Question: What is the strategy for MRD and how does it compete with larger players? - The MRD offering is unique due to its comprehensive approach, and the company is not providing specific timelines for market entry [88] Question: How is the company managing operating expenses and R&D spending? - R&D spending is expected to remain flat as most investments have already been made, allowing for strategic allocation towards sales and marketing [69][71]

Financial Performance - Total revenue increased by 81% year-over-year, reaching $181.4 million in Q2 2025, compared to $100 million in Q2 2024[11] - Molecular Profiling Services revenue grew by 86% year-over-year, amounting to $162.9 million in Q2 2025, up from $87.7 million in Q2 2024[11] - Pharma R&D Services revenue increased by 49% year-over-year, reaching $18.5 million in Q2 2025, compared to $12.4 million in Q2 2024[11] - Clinical ASP improved by 52%, rising from $2,138 in Q2 2024 to $3,256 in Q2 2025[15] - Gross margin increased by 2,514 basis points year-over-year, reaching 62.7% in Q2 2025[15, 42] - Adjusted EBITDA turned positive, reaching $16.7 million in Q2 2025, compared to a loss of $50.9 million in Q2 2024[15, 34] - Free Cash Flow turned positive, reaching $5.9 million in Q2 2025, compared to a loss of $65.5 million in Q2 2024[15, 34] Operational Highlights - Clinical volume grew by 22%, with 50,032 clinical cases completed in Q2 2025[15] - The company's molecular dataset surpassed 900,000+ comprehensive tumor patient profiles, including over 529,000 Whole Exomes and 580,000 Whole Transcriptomes[15, 21] - Caris Assure ASP increased 58.7% year-over-year to $2,519 in Q2 2025[40] - MI Profile ASP increased 53.1% year-over-year to $3,379 in Q2 2025[40] Strategic Initiatives - The Partner Oncology Alliance (POA) expanded to 97 sites with over 1,100 publications[15, 23] - A landmark Caris Assure study was published, validating the single assay across the cancer care continuum[15, 26]